IP Library Granted Patent US 8,753,590
Granted Patent B2
US 8,753,590 · App. 13/676,219 · Granted Jun 17, 2014

Purification of metals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,753,590
App. No.
13/676,219
Granted
Jun 17, 2014
Kind
B2
Abstract

A solid composition comprises: MnO 2 ; and a compound represented by the general formula (I) wherein: R is a polymer; each Y is independently a hydrogen or a negative charge; Z is either hydrogen or is not present; each n is independently 1, 2, 3, 4, 5 or 6; wherein the MnO 2 is bound to the compound of formula (I) so as to coat the surface thereof. Such a composition may be used for the separation of polyvalent metal species, such as Mo, from one or more accompanying impurities.

Claims (46)

1. A method for separating a polyvalent metal species from one or more accompanying impurities, comprising:

(i) contacting the polyvalent metal species and accompanying impurities with a composition comprising MnO 2 and a compound of formula (I):

wherein:

R is a polymer;

each Y is independently a hydrogen or a negative charge;

Z is either hydrogen or is not present;

each n is independently 1, 2, 3, 4, 5 or 6; and

wherein at least 50% of the surface of the compound of formula (I) is coated with MnO 2 so that the polyvalent metal binds to MnO 2 ;

(ii) dissolving the MnO 2 bound to the polyvalent metal to form a solution; and

(iii) contacting the solution with a complexing agent, so that the polyvalent metal binds to the compound of formula (I).

2. The method of claim 1 , wherein the method further comprises releasing the polyvalent metal species with a base.

3. The method of claim 1 , wherein the dissolution of step (ii) is facilitated with an acid.

4. The method of claim 3 , wherein the acid is sulphuric acid.

5. The method of claim 1 , wherein the polyvalent metal species is selected from the group consisting of Mn, Co, Ni, Pt, Mo, and Fe.

6. The method of claim 1 , wherein the polyvalent metal species is Mo.

7. The method of claim 1 wherein the polyvalent metal species is a radioactive isotope.

8. The method of claim 7 , wherein the polyvalent metal species is Mo-99.

9. The method of claim 1 , wherein the complexing agent in step (iii) comprises rhodanide ions.

10. The method of claim 1 , wherein step (iii) additionally comprises a reducing agent selected from the group consisting of iodide ions, sulphite ions, metallic zinc, metallic aluminum, and combinations thereof.

11. The method of claim 1 , wherein the composition comprising MnO 2 and a compound of formula (I) is provided in one or more vessels having an inlet for the introduction of a solution containing the polyvalent metal species, and an outlet for the elution of components of the solution.

12. A method for separating Mo-99 from one or more accompanying impurities, comprising:

(i) contacting the Mo-99 and the accompanying impurities with a composition comprising MnO 2 and compound of formula (I)

wherein:

R is a polymer;

each Y is independently a hydrogen or a negative charge;

Z is either hydrogen or is not present;

each n is independently 1, 2, 3, 4, 5 or 6;

wherein at least 50% of the surface of the compounds of formula (I) is coated with MnO 2 , so that Mo-99 binds to MnO 2 and

(ii) dissolving the MnO 2 bound to the Mo-99 with an acid to form a solution;

(iii) contacting the solution with a rhodanide complexing agent so that the Mo-99 binds to the compound of formula (I); and

(iv) releasing the Mo-99 bound to the compound of formula (I) with a base.

13. The method of claim 12 , wherein the composition comprising MnO 2 and a compound of formula (I) is provided in a vessel having an inlet for the introduction of a solution containing the polyvalent metal species, and an outlet for the elution of components of the solution.

14. The method of claim 12 , wherein R comprises a crosslinked polystyrene and n=1.

15. A method for producing a MnO 2 -adsorbate, wherein the method comprises contacting a manganese containing-compound chosen from KMnO 4 , MnCl 2 , or MnSO 4 , to

a compound represented by the general formula (I)

wherein:

R is a polymer;

each Y is independently a hydrogen or a negative charge;

Z is either hydrogen or is not present;

each n is independently 1, 2, 3, 4, 5 or 6; and

wherein formula (I) is coated with MnO 2 .

16. The method of claim 15 , wherein R comprises a crosslinked polystyrene and n=1.

17. The method of claim 15 , wherein the compound of formula (I) of the MnO 2 -adsorbate is coated with MnO 2 on at least 50% of its surface.

18. The method of claim 15 , wherein at least 90% of the surface of the compound of formula (I) is coated with MnO 2 .

19. The method of claim 15 , wherein the method further comprises heating the MnO 2 -adsorbate at a temperature of 60-70° C.

20. The method of claim 19 , wherein the heating is conducted over 10 to 15 hours.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 041131/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: MALLINCKRODT LLC
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 039149/0234 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →